May 4 (Reuters) - Amgen said on Monday it was investing an additional $300 million in Puerto Rico to expand its U.S.

LOS ANGELES (Reuters) -Amgen on Monday launched direct-to-consumer U.S. sales of its cholesterol-lowering medication Repatha at a discounted cash price, becoming the latest pharmaceutical company to ...

Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN) to $340 from $351 on Monday, May 4, while maintaining a ...

The additional investment builds on $650 million Amgen committed to its Juncos facility last year, which supplies medicines ...

Dr. Howard Chang, fourth from left, Amgen's senior vice president global research & chief scientific officer, with fellows in the biotech company's new postbaccalaureate fellowship program. The ...

Amgen has pulled the plug on midstage drug candidates for cancer and the autoimmune disease Sjögren’s syndrome, terminating ...

Amgen’s first quarter results reflected the company’s ability to outpace the impact of ongoing patent expirations and ...

Thousand Oaks-based Amgen continues to invest in its onshore capabilities, after the biotech giant announced plans to invest an additional $300 million in its U.S. manufacturing network to further ...

The FDA has renewed calls for Amgen’s Tavneos to be pulled from the market, saying it has discovered new evidence that study ...

Thousand Oaks pharma giant Amgen Inc. is making a series of C-suite changes, triggered by the retirement announcement of ...

Amgen is putting $300 million more into expanding its U.S. manufacturing, with the money going toward enlarging its biologics plant in Puerto Rico. The biotechnology company said Monday that the ...

Food and Drug ‌Administration's Center for Drug ‌Evaluation and Research on Monday ​proposed withdrawing approval of Amgen's ...